234 related articles for article (PubMed ID: 22160715)
1. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.
Lu J; Yang C; Chen M; Ye DY; Lonser RR; Brady RO; Zhuang Z
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21200-5. PubMed ID: 22160715
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.
Yang C; Rahimpour S; Lu J; Pacak K; Ikejiri B; Brady RO; Zhuang Z
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):966-71. PubMed ID: 23277556
[TBL] [Abstract][Full Text] [Related]
3. Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.
Yang C; Wang H; Zhu D; Hong CS; Dmitriev P; Zhang C; Li Y; Ikejiri B; Brady RO; Zhuang Z
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1137-42. PubMed ID: 25583479
[TBL] [Abstract][Full Text] [Related]
4. Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.
Yang C; Swallows CL; Zhang C; Lu J; Xiao H; Brady RO; Zhuang Z
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):249-54. PubMed ID: 24351928
[TBL] [Abstract][Full Text] [Related]
5. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.
Lu J; Chiang J; Iyer RR; Thompson E; Kaneski CR; Xu DS; Yang C; Chen M; Hodes RJ; Lonser RR; Brady RO; Zhuang Z
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21665-70. PubMed ID: 21098288
[TBL] [Abstract][Full Text] [Related]
6. ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.
Tan YL; Genereux JC; Pankow S; Aerts JM; Yates JR; Kelly JW
Chem Biol; 2014 Aug; 21(8):967-76. PubMed ID: 25126989
[TBL] [Abstract][Full Text] [Related]
7. The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
Fog CK; Zago P; Malini E; Solanko LM; Peruzzo P; Bornaes C; Magnoni R; Mehmedbasic A; Petersen NHT; Bembi B; Aerts JFMG; Dardis A; Kirkegaard T
EBioMedicine; 2018 Dec; 38():142-153. PubMed ID: 30497978
[TBL] [Abstract][Full Text] [Related]
8. Molecular regulations and therapeutic targets of Gaucher disease.
Chen Y; Sud N; Hettinghouse A; Liu CJ
Cytokine Growth Factor Rev; 2018 Jun; 41():65-74. PubMed ID: 29699937
[TBL] [Abstract][Full Text] [Related]
9. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
10. ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease.
Maor G; Filocamo M; Horowitz M
Hum Mol Genet; 2013 Apr; 22(7):1316-27. PubMed ID: 23255161
[TBL] [Abstract][Full Text] [Related]
11. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
[TBL] [Abstract][Full Text] [Related]
12. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
[TBL] [Abstract][Full Text] [Related]
13. Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease.
Liu Y; Zhao X; Jian J; Hasan S; Liu C
Biosci Trends; 2023 May; 17(2):126-135. PubMed ID: 36889696
[TBL] [Abstract][Full Text] [Related]
14. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Ron I; Rapaport D; Horowitz M
Hum Mol Genet; 2010 Oct; 19(19):3771-81. PubMed ID: 20643691
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.
Bendikov-Bar I; Ron I; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2011 Jan; 46(1):4-10. PubMed ID: 21106416
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
[TBL] [Abstract][Full Text] [Related]
17. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
Trapero A; Alfonso I; Butters TD; Llebaria A
J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
[TBL] [Abstract][Full Text] [Related]
18. Alteration of the proteostasis network of plant cells promotes the post-endoplasmic reticulum trafficking of recombinant mutant (L444P) human β-glucocerebrosidase.
Babajani G; Kermode AR
Plant Signal Behav; 2014; 9(3):e28714. PubMed ID: 24713615
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
Babajani G; Tropak MB; Mahuran DJ; Kermode AR
Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
[TBL] [Abstract][Full Text] [Related]
20. Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.
Jian J; Tian QY; Hettinghouse A; Zhao S; Liu H; Wei J; Grunig G; Zhang W; Setchell KDR; Sun Y; Overkleeft HS; Chan GL; Liu CJ
EBioMedicine; 2016 Nov; 13():212-224. PubMed ID: 27789271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
